(Arg)9 TFA
Based on 1 publication(s) in Google Scholar
(Arg)9 (Nona-L-arginine) TFA is a cell-penetrating peptide (CPP) made up of 9 arginine residues. (Arg)9 TFA has neuroprotective property, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.57%
- No. CAS: 2283335-13-5
- Fòrmula: C54H110N36O10.xC2HF3O2
- Peso molecular:1423.69 (free acid)
-
Almacenamiento:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) (Arg)9 TFA
More
Actividad biológica
IC50: 0.78 μM (neuroprotection)[1].
(Arg)9 (Nona-L-arginine; 5-10 μM) TFA provides significant neuroprotection in a dose–response manner following glutamic acid exposure (IC50=0.78 μM). Following kainic acid exposure, (Arg)9 TFA is neuroprotective, but less effective than in the glutamic acid model (IC50=0.81 μM). (Arg)9 TFA also shows neuroprotection following in vitro ischemia (IC50=6 μM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague–Dawley rats (270 to 320 g) permanent middle cerebral artery stroke model[2]
-
Dosage:1 μM/kg (600 μL)
-
Administration:Intravenous injection; once, over 5 minutes
-
Result:Reduced significantiy 20% in infarct volume.
Chemical Information
-
No. CAS 2283335-13-5
-
Appearance Solid
-
Peso molecular 1423.69 (free acid)
-
Fòrmula C54H110N36O10.xC2HF3O2
-
Color White to off-white
-
Synonyms
Nona-L-arginine TFA; Peptide R9 TFA
-
Sequence
Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg
-
Sequence Shortening
RRRRRRRRR
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvente y solubilidad
H2O : ≥ 100 mg/mL
* "≥" means soluble, but saturation unknown.
Pureza y Documentación
-
Ficha de datos (270 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Meloni BP, et, al. The neuroprotective efficacy of cell-penetrating peptides TAT, penetratin, Arg-9, and Pep-1 in glutamic acid, kainic acid, and in vitro ischemia injury models using primary cortical neuronal cultures. Cell Mol Neurobiol. 2014 Mar;34(2):173-81. [Content Brief]
[2]. Meloni BP, et, al. Poly-arginine and arginine-rich peptides are neuroprotective in stroke models. J Cereb Blood Flow Metab. 2015 Jun;35(6):993-1004. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
(Arg)9 TFA Related Classifications
HY-P0133A Related Classifications
Powered by Bioz